Genomer courtesy image

Johnson & Johnson is expanding its interests in Japan with the acquisition of Ci:z Holdings, a company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products.  Included in the $2.1 stock offer are brands including Dr.Ci:Labo, Labo Labo, and the Genomer line of skincare products.  This is Johnson & Johnson’s first departure from mass beauty, where is has a stronghold with Aveeno, Neutrogena, Clean & Clear, RoC, Lubriderm, Le Petit Marseillais, Rogaine, and several other brands.

“Health and beauty consumers are actively seeking science-based innovation to improve their skin,” said Jorge Mesquita, Worldwide Chairman, Johnson & Johnson Consumer. “This transaction will maximise value creation for Johnson & Johnson’s Consumer business by bringing in an agile innovation model and rapidly accelerating sales through our global commercialization expertise.”

In July 2016, Cilag GmbH International, an affiliate of Johnson & Johnson’s, entered into a long-term strategic collaboration with Ci:z Holdings to distribute its brands outside of Japan. As part of this collaboration, Cilag acquired approximately 19.9% of the outstanding shares of Ci:z Holdings. The tender offer is part of a series of transactions in which Johnson & Johnson intends to acquire all the outstanding shares.